en hu en cs cs cs cs cs cs sk cs hbs_lat cs cs sk de pl cs cs cs cs cs en cs cs cs cs cs cs cs sk cs hbs_lat cs cs sk sl cs cs fr cs en cs cs en en de bg ru cs et hu ur lt pl ro cs cs en en en en en en en en en en en en en en en en en en en en cs en cs pl en de en ru fr en en en cs hu cs cs fr cs fr en cs cs cs cs cs cs sk cs hbs_lat cs cs sk de pl cs cs cs cs cs en cs cs cs cs cs cs cs sk cs hbs_lat cs cs sk sl cs cs fr cs en en cs cs cs cs cs hbs_lat sk cs cs sk en en en en en en en en en en en en en en en en en ml et de en en en de en en en de en en en en en en en en en en en en en
Lessons learned? The EU on its way to a new approach in pharmaceutical regulation. Feedback from CEE countries to the EU Strategy.
Many EU initiatives have seen the light of day in recent months to renew EU policy and regulation in the pharmaceutical sector. All of them will form bricks to build a stronger European Health Union.
• to establish a new institution on EU levels – the Health Emergency Preparedness and Response Authority;
• to create a European Health Data Space;
• to adopt a Health Technology Assessment Regulation;
• to contribute to the European Pillar of Social Rights;
• to align the pharmaceutical sector to other EU projects.
In addition, at the end of 2020 the EU initiated the renewal of the Pharmaceutical Strategy for Europe, revising pharmaceutical legislation to address potential weaknesses with the following major goals:
• delivering for patients – unmet medical needs and unequal access to medicines for patients across the EU;
• a competitive and sound legislative framework to quickly respond to innovation and enabling digital transformation;
• enhancing resilience – securing supply of environmentally sustainable medicines and enhancing EU health crisis mechanisms.
The Pharmaceutical Strategy and the Combined Evaluation Roadmap/Inception Impact Assessment draws conclusions not only from application of current EU pharmaceutical legal acts but also from issues experienced during COVID-19.
Initial feedback from all interested persons was collected by the end of April 2021.
Different opinions were received from pharma associations and institutes of CEE countries with generally positive feedback to the initiatives as such.
However, many opinions stress the fact that inequalities in access to medicines and affordability will not be resolved solely by EU regulation since they also originate also from the size of markets, national regulations (especially pricing & reimbursement), national timelines and readiness of national health systems. This was stressed by the Romanian Association of International Pharmaceutical Producers, the Polish INFARMA, and the Lithuanian Free Market Institute.
The AIFP of the Czech Republic suggests that the legislative framework should allow policy adaptions at a later stage without the need to revise the whole legislation anew.
Suggestions from the lessons of COVID-19 include enhancing the process of resource allocation, reforming procurement, rationalizing stockpiling away from uncoordinated national stockpiling demands, and use of data from national databases due to the Falsified Medicines Directive.
Stisknutím 'Odebírat' souhlasíte s našimi podmínkami pro zpracování dat
English, German, Lithuanian, Russian
EN DE BG RU CS ET HU LV LT PL RO SK
Korporátní právo a M&A
Life Sciences & Pharma
We use cookies for proper and safe functioning of our website; however, if you give us your consent by clicking on the box(es) below, we may also use cookies to maintain your preferred settings, for statistics and marketing purposes. By clicking on the „I confirm“ button, you confirm your choice of cookies we may use. For more information, please see our
This website uses cookies
Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
Data is sent to: Germany (adequate) Adequate country under GDPR (EU) Blocked until accepted by user: No
Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in. We currently do not use this type of cookies.
Statistics cookies collect information about how you use a website, like which pages you visited and which links you clicked on. We currently do not use this type of cookies.
Marketing cookies track your online activity to help advertisers deliver more relevant advertising or to limit how many times you see an ad. We currently do not use this type of cookies.